4 companies filing this week (09 Nov - 13 Nov)

Last week we skipped our issue because there were no IPOs planned in the US amid the elections.

This week there are 4 companies filing to go public, 3 of them in the Health Care sector.

---

Compass Therapeutics (CMPX) [2014]

Health Care | 9,000,000 shares | $5.00 - $6.00 | Nasdaq

Compass Therapeutics is a clinical-stage biotechnology company targeting the human immune synapse with a new generation of antibody therapeutics. Compass has broadly drugged the immune system by generating epitopically diverse antibody panels to more than 40 targets across all immune cell types and is leveraging its proprietary StitchMabs and common light-chain based multispecific platforms to empirically identify combinations and multispecific with optimized activity.

Website | SEC report | Bloomberg | Crunchbase

IN8bio (INAB) [2016]

Health Care | 4,687,500 shares | $15.00 - $17.00 | Nasdaq

Incysus Therapeutics is a operator of a biotechnology company intended to develop immune-based therapies for the treatment of cancer. The company’s services focus on utilizing genetically modified gamma-delta T cells across a Drug Resistance Immunotherapy (DRI) platform that addresses the challenges faced while targeting cold, low mutation cancers, enabling the targeting of malignant cells and potentially more effective treatments for patients with difficult-to-treat solid tumor cancers.

Website | SEC report | Bloomberg | Crunchbase

Inhibikase Therapeutics (IKT) [2008]

Health Care | 1,363,636 shares | $10.00 - $12.00 | Nasdaq

Inhibikase Therapeutics has developed the first small molecule platform capable of treating both bacterial and viral infectious disease through a common mechanism of action in the host. The Company’s host targeting strategy creates multi-pathogen anti-infectives without stimulating resistance.

Website | SEC report | Bloomberg | Crunchbase

Natural Order Acquisition (NOACU) [2020]

Financial Services | 20,000,000 shares | $10.00 | Nasdaq

Natural Order Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.

SEC report | Bloomberg